These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 22237659)
41. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer. Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726 [TBL] [Abstract][Full Text] [Related]
42. Neoadjuvant chemotherapy with a combination of docetaxel, cisplatin, fluorouracil, and leucovorin in nonresectable advanced gastric cancer: a short communication. Ma Y; Qin H; Zheng Q; Wang Y; Wang Z; Yang Z Med Oncol; 2010 Dec; 27(4):1089-95. PubMed ID: 19885749 [TBL] [Abstract][Full Text] [Related]
43. A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Kollmannsberger C; Quietzsch D; Haag C; Lingenfelser T; Schroeder M; Hartmann JT; Baronius W; Hempel V; Clemens M; Kanz L; Bokemeyer C Br J Cancer; 2000 Aug; 83(4):458-62. PubMed ID: 10945491 [TBL] [Abstract][Full Text] [Related]
44. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer. Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628 [TBL] [Abstract][Full Text] [Related]
45. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD; Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686 [TBL] [Abstract][Full Text] [Related]
46. Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer. Oh DY; Kim TY; Kwon JH; Lee JJ; Joh Y; Kim DW; Kim TY; Heo DS; Bang YJ; Kim NK Jpn J Clin Oncol; 2005 Jul; 35(7):380-5. PubMed ID: 15976069 [TBL] [Abstract][Full Text] [Related]
47. A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas. Caroli-Bosc FX; Van Laethem JL; Michel P; Gay F; Hendlisz A; Forget F; Bleiberg H Eur J Cancer; 2001 Oct; 37(15):1828-32. PubMed ID: 11576835 [TBL] [Abstract][Full Text] [Related]
48. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Ott K; Sendler A; Becker K; Dittler HJ; Helmberger H; Busch R; Kollmannsberger C; Siewert JR; Fink U Gastric Cancer; 2003; 6(3):159-67. PubMed ID: 14520529 [TBL] [Abstract][Full Text] [Related]
49. A phase II study of docetaxel and cisplatin in patients with gastric cancer recurring after or progressing during 5-FU/platinum treatment. Kim H; Park JH; Bang SJ; Kim DH; Cho HR; Kim GY; Min YJ Jpn J Clin Oncol; 2005 Dec; 35(12):727-32. PubMed ID: 16332720 [TBL] [Abstract][Full Text] [Related]
50. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517 [TBL] [Abstract][Full Text] [Related]
51. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. Shah MA; Janjigian YY; Stoller R; Shibata S; Kemeny M; Krishnamurthi S; Su YB; Ocean A; Capanu M; Mehrotra B; Ritch P; Henderson C; Kelsen DP J Clin Oncol; 2015 Nov; 33(33):3874-9. PubMed ID: 26438119 [TBL] [Abstract][Full Text] [Related]
52. Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer. Quintero-Aldana G; Jorge M; Grande C; Salgado M; Gallardo E; Varela S; López C; Villanueva MJ; Fernández A; Alvarez E; González P; Castellanos J; Casal J; López R; Campos Balea B Cancer Chemother Pharmacol; 2015 Oct; 76(4):731-7. PubMed ID: 26242221 [TBL] [Abstract][Full Text] [Related]
53. Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma. Bayraktar UD; Bayraktar S; Hosein P; Chen E; Koniaris LG; Rocha-Lima CM; Montero AJ Med Oncol; 2012 Sep; 29(3):1707-10. PubMed ID: 22033912 [TBL] [Abstract][Full Text] [Related]
54. A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. Graziano F; Santini D; Testa E; Catalano V; Beretta GD; Mosconi S; Tonini G; Lai V; Labianca R; Cascinu S Br J Cancer; 2003 Oct; 89(8):1428-32. PubMed ID: 14562012 [TBL] [Abstract][Full Text] [Related]
55. A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen. Kim SH; Lee GW; Go SI; Cho SH; Kim HJ; Kim HG; Kang JH Am J Clin Oncol; 2010 Dec; 33(6):572-6. PubMed ID: 20042971 [TBL] [Abstract][Full Text] [Related]
56. Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study. Deleporte A; Van den Eynde M; Forget F; Holbrechts S; Delaunoit T; Houbiers G; Kalantari HR; Laurent S; Vanderstraeten E; De Man M; Vergauwe P; Clausse M; Van Der Auwera J; D'Hondt L; Pierre P; Ghillemijn B; Covas A; Paesmans M; Ameye L; Awada A; Sclafani F; Hendlisz A Cancer Med; 2021 Jul; 10(13):4366-4374. PubMed ID: 34057299 [TBL] [Abstract][Full Text] [Related]
57. Efficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2. Turkeli M; Aldemir MN; Cayir K; Simsek M; Bilici M; Tekin SB; Yildirim N; Bilen N; Makas I Asian Pac J Cancer Prev; 2015; 16(3):985-9. PubMed ID: 25735393 [TBL] [Abstract][Full Text] [Related]
58. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study. Tsuji K; Yasui H; Onozawa Y; Boku N; Doyama H; Fukutomi A; Yamazaki K; Machida N; Todaka A; Taniguchi H; Tsushima T; Yokota T Jpn J Clin Oncol; 2012 Aug; 42(8):686-90. PubMed ID: 22693245 [TBL] [Abstract][Full Text] [Related]
59. Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer. Kucukzeybek Y; Dirican A; Erten C; Somali I; Can A; Demir L; Bayoglu IV; Akyol M; Medeni M; Tarhan MO Asian Pac J Cancer Prev; 2012; 13(6):2771-4. PubMed ID: 22938457 [TBL] [Abstract][Full Text] [Related]
60. Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma. Park SR; Chun JH; Kim YW; Lee JH; Choi IJ; Kim CG; Lee JS; Bae JM; Kim HK Am J Clin Oncol; 2005 Oct; 28(5):433-8. PubMed ID: 16199979 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]